Whitepaper

Acacia Research: Undervalued Biotech Tentacles

2021-06-28T12:46:57+00:00

In this research note, Formidable takes a deep dive into Acacia Research Corporation (NASDAQ: ACTG), which represents an investment opportunity in secondary private equity, as well as patent litigation (its historical bailiwick). See below for the company’s mission statement, pulled from its website.

Acacia Research: Undervalued Biotech Tentacles2021-06-28T12:46:57+00:00

Nano One Update: After the Capital Raise…

2021-03-26T20:00:24+00:00

Nano One recently issued stock at $5.35 Canadian to raise a total of $25M. While we were first concerned about this decision, after speaking to the company, we feel more sanguine about the prospects for this capital. Obviously, dilution is nothing we cheer, especially as shareholders of a company without earnings currently. But the impetus behind it, per our discussion with the company, is that its customer base is demanding larger proof of concept deliverables.

Nano One Update: After the Capital Raise…2021-03-26T20:00:24+00:00